Valuation : Gilead Sciences, Inc.

Market Cap 181B 155B 147B 134B 250B 17,267B 252B 1,745B 672B 8,758B 678B 663B 27,818B P/E 2026 *
-44.1x
P/E 2027 * 18.2x
Enterprise Value 197B 170B 160B 146B 273B 18,868B 275B 1,907B 734B 9,570B 741B 725B 30,397B EV / Sales 2026 *
6.43x
EV / Sales 2027 * 5.81x
Free-Float
99.88%
Yield 2026 *
2.26%
Yield 2027 * 2.3%
1 day-0.83%
1 week-4.57%
Current month-1.39%
1 month+8.45%
3 months+18.79%
6 months-2.86%
Current year+17.57%
1 week 143.67
Extreme 143.67
151.18
1 month 132.01
Extreme 132.01
152.55
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 A Sell

Chief Executive Officer

-15,000 0.0012%
8/26/26 A Exercice

Director

54,000 0.0043%
8/20/26 A Exercice

Director

15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.83%-4.57%+25.21%+87.31% 181B
+0.24%-3.05%+48.98%+88.77% 1,002B
-0.26%-4.48%+51.29%+63.51% 644B
+0.64%-3.21%+19.01%+68.99% 443B
-0.63%-3.09%+29.84%+36.08% 343B
+0.43%-14.61%+11.32%+26.98% 262B
+0.93%-3.19%-1.31%+11.96% 245B
-2.25%-13.73%+37.57%+46.39% 212B
-0.90%-5.06%-18.47%-58.14% 199B
-1.03%-4.55%+11.93%-18.97% 158B
Average -0.23%-4.92%+21.54%+35.29% 368.8B
Weighted average by Cap. -0.06%-4.24%+30.94%+52.55%

Financials

2026 *2027 *
Net sales 30.69B 26.39B 24.9B 22.69B 42.41B 2,934B 42.79B 297B 114B 1,488B 115B 113B 4,727B 32.68B 28.11B 26.52B 24.16B 45.16B 3,125B 45.57B 316B 122B 1,585B 123B 120B 5,034B
Net income -4.27B -3.68B -3.47B -3.16B -5.91B -409B -5.96B -41.31B -15.9B -207B -16.05B -15.7B -658B 10.28B 8.84B 8.34B 7.6B 14.2B 982B 14.33B 99.3B 38.22B 498B 38.58B 37.74B 1,583B
Net Debt 16.75B 14.4B 13.59B 12.38B 23.14B 1,601B 23.35B 162B 62.28B 812B 62.88B 61.51B 2,579B 9.12B 7.85B 7.4B 6.74B 12.61B 872B 12.72B 88.18B 33.94B 442B 34.26B 33.52B 1,405B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
10/09/26 $144.38 -0.87% 1,245,169
09/09/26 $145.65 -0.68% 4,583,213
08/09/26 $146.64 -2.88% 6,080,502
04/09/26 $151.00 -0.15% 6,181,783
03/09/26 $151.22 +1.08% 4,498,099
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
145.65USD
Average target price
158.15USD
Spread / Average Target
+8.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!